Infusion pumps are commonly used for infusion of drugs for physiologic control, and infusion rate has been demonstrated to affect the parameters of pharmacokinetic models. In attempting to develop a model that explained this behavior, we examined the behavior of the Graseby 3400 syringe pump under a range of flow conditions and with variations in syringe characteristics. Two issues were identified: start-up loss (the difference between actual and ideal delivery on initial infusion) and update loss (the difference between actual and ideal delivery when transmitting a command to change infusion rate). Under worst-case conditions, this may result in a 20-second period of zero delivery during start-up, and when updating infusion rates once per second, zero output. These effects are influenced by syringe characteristics and vary sufficiently as to make it impossible to isolate this effect from the pharmacokinetic process being controlled. The implications of this for previous published results and clinical application of target-controlled infusions are discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1213/01.ane.0000438349.21617.2f | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preclinical Alzheimer's prevention trials require a multi-year commitment from diverse, cognitively unimpaired individuals willing to receive biomarker results of confirmed Alzheimer's pathology and possible ApoE4 status. Participants learn new terms such as ARIA, edema and microhemorrhage and undergo numerous MRI scans for safety monitoring. They take quarterly composite Alzheimer's assessments that are anxiety-provoking and highlight weaknesses which may have been unrecognized in daily life.
View Article and Find Full Text PDFUpdates on Chimeric Antigen Receptor T-Cells in Large B-Cell Lymphoma.
Biomedicines
December 2024
International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France.
CD19-targeting chimeric antigen receptor (CAR) T-cells have changed the treatment paradigm of patients with large B-cell lymphoma (LBCL). Three CAR T-cells were approved by the Food and Drug Administration (FDA) for patients with relapsed and/or refractory (R/R) LBCL in the third-line setting: tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), and lisocabtagene maraleucel (liso-cel), with an ORR ranging from 58% to 82%. More recently, axi-cel and liso-cel were approved as second-line treatments for patients with R/R disease up to 12 months after the completion of first-line chemo-immunotherapy.
View Article and Find Full Text PDFEfficacy, Indications, and Safety of Intrathecal Baclofen Pump: A Narrative Review.
Curr Pain Headache Rep
January 2025
Department of Anesthesiology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, 71103, USA.
Purpose Of Review: Baclofen, a muscle relaxant that reduces the release of excitatory neurotransmitters in the pre-synaptic neurons stimulating inhibitory neuronal signals in post-synaptic neurons, has been around for over 5 decades. Baclofen is used primarily for spasticity and since 1982, has had a role as an intrathecal agent. In the present investigation, we review research trends and updates on safety and efficacy of intrathecal baclofen (ITB) pumps.
View Article and Find Full Text PDFManaging Intracranial Pressure Crisis.
Curr Neurol Neurosci Rep
December 2024
Division of Critical Care, Department of Medicine, Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkok, 10700, Thailand.
Article Synopsis
- The review aims to establish a detailed management protocol for treating intracranial pressure (ICP) crises based on the latest research findings.
- It highlights crucial elements of critical care for ICP management, including ventilation, fluid therapy, and ICP monitoring, which can significantly influence patient outcomes.
- The article suggests that ongoing research is needed to create effective intervention protocols for both invasive and noninvasive neuromonitoring techniques in ICP cases.
Evaluation of Response to Weight-based Dosing Strategies of Continuous, Fixed-Rate Atracurium Infusions in Critically Ill, Obese Adults With Acute Respiratory Distress Syndrome.
Ann Pharmacother
December 2024
Department of Pharmacy, Cleveland Clinic, Cleveland, OH, USA.
Article Synopsis
- The study investigates the effectiveness of two weight-based dosing strategies for atracurium in obese patients with acute respiratory distress syndrome (ARDS) during the COVID pandemic, focusing on oxygenation changes after treatment.
- It compares the outcomes of patients receiving atracurium based on actual body weight (ABW) versus ideal body weight (IBW), finding no significant difference in oxygenation improvement after 48 hours despite different dosing amounts.
- The results indicated higher atracurium doses in the ABW group, but no differences in mortality rates or days free from ICU or ventilator support, suggesting both dosing methods may be equally viable for this patient population.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!